University of Pennsylvania: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials

The registry lists 16 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with University of Pennsylvania as lead sponsor. 2 are open to participants now and 5 have results posted.

Phase 1 10Phase 2 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ CancersNot yet recruitingNCT07891468Phase 1
• Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in ChildrenRecruitingNCT06529575
• Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate GrowthCompletedNCT05230004Not applicableResults posted
• Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALLCompletedNCT03792633Phase 2Results posted
• CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALLTerminatedNCT02935543Phase 2Results posted
• Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02030847Phase 2Results posted
• CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to ChemotherapyCompletedNCT01029366Phase 1Results posted
• Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and LymphomaWithdrawnNCT05037669Phase 1
• huCART19-IL18 in CD19+ CancersActive, not recruitingNCT04684563Phase 1
• PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor DisabilityCompletedNCT04321200
• CART22 Alone or in Combination With huCART19 for ALLActive, not recruitingNCT03620058Phase 1
• Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release SyndromeCompletedNCT02906371Phase 1
• Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT02588456Phase 1
• Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell TherapyCompletedNCT02374333Phase 1
• Allo CART-19 ProtocolTerminatedNCT01551043Phase 1
• Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantTerminatedNCT00674427Phase 1